1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,920 | 2,180 | 23:01 | |
| 2,040 | 2,060 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ACLARION Aktie jetzt für 0€ handeln | |||||
| Do | Aclarion adds University of Arizona to Nociscan spine trial | 1 | Investing.com | ||
| 12.08. | Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process | 399 | GlobeNewswire (Europe) | Patent protects the precision of MRS data capture within the target disc - a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver... ► Artikel lesen | |
| 06.08. | Aclarion, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Aclarion, Inc.: Aclarion Announces Nociscan Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology | 1 | GlobeNewswire (USA) | ||
| 29.07. | Aclarion: Scan-Volumen im ersten Halbjahr 2026 um 141 % gestiegen | 3 | Investing.com Deutsch | ||
| 29.07. | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 | 515 | GlobeNewswire (Europe) | 141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA... ► Artikel lesen | |
| 09.07. | Aclarion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.07. | Aclarion adds Texas Spine Care Center to CLARITY trial | 1 | Investing.com | ||
| 07.07. | Aclarion erweitert CLARITY-Studie um Texas Spine Care Center | 2 | Investing.com Deutsch | ||
| 07.07. | Aclarion, Inc.: Aclarion Announces Texas Spine Care Center as New CLARITY Site | 1 | GlobeNewswire (USA) | ||
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 344 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 810 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 08.06. | Aclarion, Inc.: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | 220 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 04.06. | Aclarion, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.06. | Aclarion, Inc.: Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation | 2 | GlobeNewswire (USA) | ||
| 01.06. | Aclarion's Nociscan technology used in back pain study | 2 | Investing.com | ||
| 01.06. | Aclarion, Inc.: Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 317,00 | -0,42 % | Intuitive Surgical: Exzellentes Geschäftsmodell, aber ist die Aktie jetzt zu teuer? | Intuitive Surgical gilt als Qualitätsunternehmen mit dominierender Marktstellung in der roboterassistierten Chirurgie, doch die aktuelle Bewertung der Aktie erscheint angesichts der jüngsten Kennzahlen... ► Artikel lesen | |
| UNITEDHEALTH | 344,60 | +1,47 % | Billionaire David Tepper Sold Every Single Share of UnitedHealth in Q2. Here's Whether He Made a Costly Mistake. | ||
| THERMO FISHER | 545,00 | +1,30 % | Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside? | ||
| ATOSSA THERAPEUTICS | 2,300 | 0,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 56,30 | +1,15 % | Centene: Deutliche Margenerholung - warum der Markt die neue Gewinnqualität noch immer unterschätzt | Centene verzeichnet eine klare Margenerholung im Kerngeschäft und erhöht seine Ergebnisziele, während die Bewertung im historischen Vergleich moderat bleibt. Die Aktie hat sich zwar bereits deutlich... ► Artikel lesen | |
| QUIDELORTHO | 12,285 | -4,66 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,800 | +3,32 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,080 | -2,70 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 0,863 | +0,02 % | Nano-X Imaging Ltd: Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026 | ||
| FULGENT GENETICS | 17,000 | -0,58 % | Fulgent expects $330M-$340M 2026 revenue as billing transition lowers collection rates | ||
| LANTHEUS | 86,00 | -0,46 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease | BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,814 | -0,28 % | BMO initiates Perspective Therapeutics stock at Outperform, $11 target | ||
| OMNICELL | 30,000 | +4,90 % | OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth | ||
| AMN HEALTHCARE SERVICES | 29,000 | -0,68 % | AMN Healthcare Services, Inc.: Amn Healthcare Announces Second Quarter 2026 Results | Quarterly revenue of $673 million and adjusted EBITDA of $73 million;
GAAP income of $0.53/share and adjusted EPS of $0.77
DALLAS, Aug. 6, 2026 /PRNewswire/ --... ► Artikel lesen |
Das Unternehmen ACLARION INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,930 Euro und damit -7,21 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.